Showing 3121-3130 of 4063 results for "".
- Genentech: Largest Real-World Studies Show Vabysmo’s Long-Term Benefits for Wet AMD, DMEhttps://modernod.com/news/genentech-largest-real-world-studies-show-vabysmos-long-term-benefits-for-wet-amd-dme/2482798/Genentech presented more than 20 abstracts across its ophthalmology portfolio at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting. Key studies highlight Vabysmo’s long-term ability to sustain vision improvements in patients with wet
- Valitor Presents Preclinical Datasets on the Potential of its Anti-VEGF Therapy Dosed Twice Yearly for Wet AMDhttps://modernod.com/news/valitor-presents-preclinical-datasets-on-the-potential-of-its-anti-vegf-therapy-dosed-twice-yearly-for-wet-amd/2482790/Valitor announced data from VLTR-559, its long-acting anti-VEGF biologic in development for its wet age-related macular degeneration (AMD) treatment, and its multivalent polymer (MVP) technology platform, were presented at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annua
- Versea Ophthalmics Announces Novel Application of Biovance Product Portfolio in Retinal Procedureshttps://modernod.com/news/versea-ophthalmics-announces-novel-application-of-biovance-product-portfolio-in-retinal-procedures/2482787/Verséa Ophthalmics has announced that results from recent application of Biovance and Biovance 3L Ocular products in macular hole repair will be presented at the upcoming Retinal World Congress (RWC) being held from May 8-11, 2025 in Fort Lauderdale, FL. The macula
- Johnson & Johnson to Present New Scientific Data on Acuvue Oasys Max 1-Day, Tecnis Odyssey, and a Purely Refractive Next Generation EDF IOL at ARVOhttps://modernod.com/news/johnson-johnson-to-present-new-scientific-data-on-acuvue-oasys-max-1-day-tecnis-odyssey-and-a-purely-refractive-next-generation-edf-iol-at-arvo/2482783/Johnson & Johnson will present new data on several of its latest innovations through 35+ posters and oral presentations at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting, May 4-8. New in-vitro methodology shows that Acuvue Oasys Max&nb
- Chengdu Origen and Vanotech Announce First Patient Dosed in Phase 1 Trial of Gene Therapy for Wet AMDhttps://modernod.com/news/chengdu-origen-and-vanotech-announce-first-patient-dosed-in-phase-1-trial-of-gene-therapy-for-wet-amd/2482781/Chengdu Origen Biotechnology and Vanotech announced that the first patient dosed in the VAN-2401 multicenter phase 1 clinical trial evaluating treatment with KH658 for patients with wet age-related macular degeneration (AMD). This multicenter, open-lab
- Sydnexis Announces Three Abstracts Accepted for Poster Presentations at ARVOhttps://modernod.com/news/sydnexis-announces-three-abstracts-accepted-for-poster-presentations-at-arvo/2482780/Sydnexis announced that three abstracts have been accepted for poster presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2025 meeting taking place from May 4 to 8 in Salt Lake City. These posters present clinical data related to the STAR Study
- 4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DMEhttps://modernod.com/news/4dmt-announces-rmat-designation-granted-by-fda-for-4d-150-for-dme/2482776/4D Molecular Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the treatment of diabetic macular edema (DME). RMAT designation is part of the 21st Century Cures Act and was created to expedite the developmen
- Oculis to Present Its Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferenceshttps://modernod.com/news/oculis-to-present-its-innovative-late-stage-pipeline-candidates-at-upcoming-ophthalmology-conferences/2482774/Oculis Holding AG announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC). The presentation of the DME AWARE Delphi Stud
- Nanoscope to Present New Data for Optogenetic Therapy for RP at Eyecelerator and ARVOhttps://modernod.com/news/nanoscope-to-present-new-data-for-optogenetic-therapy-for-rp-at-eyecelerator-and-arvo/2482769/Nanoscope Therapeutics announced participation at both the Eyecelerator and The Association for Research and Vision in Ophthalmology (ARVO) 2025 annual meetings. Nanoscope’s presentations will be centered around 126-week outcomes following treatment with its MCO-010
- Nordic Pharma Presents Data and Patient Experience Study for Lacrifill Canalicular Gel at ASCRShttps://modernod.com/news/nordic-pharma-presents-data-and-patient-experience-study-for-lacrifill-canalicular-gel-at-ascrs/2482756/Nordic Pharma will be presenting recently published patient data and patient experience study for Lacrifill Canalicular Gel, a novel therapy for dry eye symptoms, during the ASCRS annual meeting in Los Angeles. The April issue of Ca